- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Cantrixil is being developed as a new treatment option for women with later-stage ovarian cancer who received limited benefit from existing chemotherapy. The drug could enable intraperitoneal (IP) chemotherapy to again become a viable treatment option in patients where it has become ineffective due to resistance.
In this interview with NDF Research’s Senior Analyst Stuart Roberts, Kazia’s CEO Dr James Garner discusses: